Laurus Labs shares rise despite weak Q2, analysts say valuations expensive

At 48 times the FY26 price-to-earnings estimate, Kotak believes that the long-anticipated earnings recovery is fully factored in, retaining a ‘Sell’ rating due to expensive valuations.

Leave a Reply

Your email address will not be published. Required fields are marked *